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1. Introduction
All procedures in medicine require a rigorous evi-
dence base to inform clinical decisions and thereby
maximise effectiveness and minimise complications.
Even when every precaution has been taken to reduce
complications, due diligence is required to recognise
unexpected events as early as possible. At the same time,
a thorough understanding of the mechanism of action
of a procedure will help to maximise the therapeutic
beneﬁts. In the following paragraphs, some of the
most important technical aspects of selective internal
radiation therapy (SIRT) are discussed.
2. Selectivity
Selectivity in the treatment of the tumour(s) is deter-
mined by the microcatheter positioning in the artery/
arteries. 1 This can be complicated by the heterogeneous
pattern of vessels and occasionally a substantial part of
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a tumour cannot be accessed because the afferent vessel
has not been detected. 2−5 In these cases, tumour pro-
gression after an endovascular treatment should not be
considered “recurrence” but rather “treatment failure”.
The aim of the procedure is to provoke the necrosis
of the tumour. Riaz and colleagues (2009) 6 observed
that it may take up to 6 months to achieve a complete
response (100% necrosis in 68% of cases at 6 months)
and that complete responses are more common in small
tumours (100% necrosis in tumours <3 cm in 89% of
cases). Another publication from the same group has
recently presented results on a novel approach, namely
radiation segmentectomy, which was associated with an
improvement in both the safety and efﬁcacy of SIRT in
hepatocellular carcinoma. During this procedure, SIRT
was applied as selectively as possible to relatively small
tumours (median tumoral volume 110 cc) resulting in
a response in 81% of 84 cases according to European
Association for the Study of the Liver (EASL) necrosis
criteria. Median time to progression in this case
series was 13.6 months (95% conﬁdence interval, 9.3–
18.7 months) and median survival was 26.9 months
(95% conﬁdence interval, 20.5–30.2 months). 7
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3. Histologic response
As mentioned previously, the intra-tumoral effect of
SIRT evolves over time. 6 SIRT provokes areas of
conﬂuent necrosis and hemorrhage leading to ﬁbrosis
and regenerative activity at tumour peripheries. The
signiﬁcant tumour necrosis associated with SIRT may
not be accompanied initially by a corresponding decrease
in size. 8 This is most probably the reason why the
EASL necrosis criteria can detect tumoral responses
at an earlier time and in more cases than other
methods based on volumetric measurements. 9,10 Some
preliminary reports have shown that there is no vascular
endothelial damage to the major vessel walls.
Depending on the size of the microspheres and the cal-
iber of the arteries at the portal space,most microspheres
are conﬁned within the portal space and very seldom
enter the sinusoids. 11 Previous experimental studies
have demonstrated, however that the microspheres (not
loaded with yttrium-90 [90Y]) may enter the sinusoids
and even may be very close to the central veins of the
lobule. 12 This area, and the surrounding sinusoids, can
be very sensitive to radiation, and when irradiated, is
associated with intimal vein ﬁbrosis, thrombosis and
sinusoidal congestion (a kind of veno-occlusive disease),
which generates a speciﬁc syndrome (4 to 8 weeks
after radiation) manifested as jaundice and ascites.
This syndrome, described by Sangro et al., is called
RadioEmbolization Induced Liver Disease (REILD) and
occurs in 4−10% of cases. 13
Since most of the microspheres remain lodged within
the portal space, radiation may provoke a kind of portal
triaditis to the healthy, non-tumoral liver. 11 With the
passage of time, this portion of the liver becomes ﬁbrotic
and decreases in volume. With whole-liver treatment,
liver ﬁbrosis is associated with portal hypertension as
evidenced by the presence of splenomegaly. 14
A very interesting ﬁnding, initially described by Sangro
et al. (2009), 15 has been carefully evaluated by Gaba
et al. (2009). 16 In their report, they demonstrate that the
ipsilateral treated liver may decrease in size by as much
as 52% and that the contralateral untreated liver may
increase in size in as much as 40%. This volumetric
change is similar to that obtained with direct portal vein
embolisation.
4. Conclusions
In conclusion, SIRT has opened the door to new
treatment options as part of the global therapeutic
strategy for patients with liver tumours. 17 SIRT should be
tailored to the individual needs of the patient depending
on their tumour burden, liver function and possible
future treatment (including surgery), with consideration
given to both the activity administered and also the
volume of liver treated (both tumoral and non-tumoral).
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